Biotechnology and Pharmaceuticals · global
Brenus Raises an Additional €11 Million to Advance Colorectal Cancer Cell Immunotherapy Trial
The new funding will support completion of dose escalation for STC-1010, expansion of the patient cohort, and preparations for the next candidate therapy; however, the existing clinical signals come from only a small number of patients, and the effects of chemotherapy itself cannot yet be ruled out.
For most patients with metastatic colorectal cancer, immune checkpoint inhibitors remain quite limited in effectiveness. Lyon, France-based biotechnology company Brenus Pharma has now raised an additional €11 million as it seeks to move an off-the-shelf cell immunotherapy through the most critical stage of early clinical development: identifying an appropriate dose and determining whether it can provide additional benefit beyond standard treatment.
This Series A extension brings Brenus’ stated total funding since its founding to €38 million. Existing investors continued to participate, while local media reported that Belgium’s Sambrinvest and South Korea’s Korea Omega Investment Corp joined as new investors. The company said the funding will be used to complete Phase 1 development of STC-1010 while preparing a second candidate therapy.
STC-1010 targets microsatellite-stable metastatic colorectal cancer, a population commonly described as having immunologically less responsive “cold tumors.” Brenus uses allogeneic tumor cells to produce a product that can be prepared in advance, designed to present the immune system with multiple tumor-associated signals and induce a broader anticancer response; this biological concept still awaits confirmation in human trials.
The ongoing BreAK-CRC001 study is an open-label, multicenter Phase 1/2a trial. The initial portion is expected to enroll approximately 21 to 33 people in Europe, beginning with dose escalation followed by cohort expansion. STC-1010 is not used alone but in combination with two immune stimulants and standard mFOLFOX6 chemotherapy, with or without bevacizumab.
Preliminary data disclosed as of early 2026 covered only six patients in the first two dose levels. Researchers reported that most infusion-related reactions were Grade 1 and that no dose-limiting toxicities were observed; two patients had partial responses, while one had stable disease. These results were sufficient to support continued dose escalation, but they were not enough to demonstrate efficacy.
Background
The central challenge in interpreting the results is that all participants also receive chemotherapy with antitumor activity, and the trial has no control group. The tumor shrinkage observed at this stage cannot be attributed to STC-1010; even if more responses emerge in subsequent cohorts, they will still need to be assessed alongside response duration, safety, immune biomarkers, and careful comparisons with historical treatment outcomes.
The financing therefore does not buy a definitive conclusion on efficacy, but rather the time and sample size needed to obtain more interpretable evidence. Brenus must next show in the expanded cohort what, precisely, this cell immunotherapy adds, and demonstrate that the safety and immune-response signals can be reproduced in more patients, before it can establish a credible foundation for subsequent controlled trials.